Avecia Biotechnology Inc. and Pfizer Inc. Enter into Manufacturing Agreement

MILFORD, Mass.--(BUSINESS WIRE)--Avecia Biotechnology, Inc., a leading provider of drug development and manufacturing services for oligonucleotide therapeutics, has reached agreement with Pfizer Inc. regarding the commercial supply of a key component of MacugenĀ® (pegaptanib sodium injection), marketed in the E.U. by Pfizer for the treatment of wet Age-Related Macular Degeneration.

Back to news